Doxercalciferol

Doxercalciferol is a synthetic vitamin D analog that plays a crucial role in the regulation of calcium and phosphorus metabolism. It is primarily used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD). Doxercalciferol acts by inhibiting the secretion of parathyroid hormone (PTH) by the parathyroid gland, which is often elevated in patients with CKD.

Mechanism of Action[edit | edit source]

Doxercalciferol is activated in the liver to form its active metabolite, 1α,25-dihydroxyvitamin D2. This active form binds to the vitamin D receptor (VDR) in the parathyroid gland, leading to a decrease in PTH secretion. The reduction in PTH levels helps to normalize serum calcium and phosphorus levels, thereby mitigating the risk of bone disease associated with secondary hyperparathyroidism.

Indications[edit | edit source]

Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. It is also used in patients with CKD not yet on dialysis to reduce elevated levels of PTH.

Pharmacokinetics[edit | edit source]

After administration, doxercalciferol is rapidly absorbed and undergoes activation in the liver. Its pharmacokinetics may vary among individuals, particularly in patients with liver impairment, which can affect the drug's activation.

Side Effects[edit | edit source]

The use of doxercalciferol can lead to several side effects, including hypercalcemia (high calcium levels in the blood), hyperphosphatemia (high phosphate levels in the blood), and hypercalciuria (high calcium levels in the urine). Monitoring of serum calcium and phosphorus levels is recommended during treatment.

Administration and Dosage[edit | edit source]

Doxercalciferol is available in both oral and intravenous formulations. The dosage is individualized based on the patient's baseline PTH levels, and adjustments are made based on the response and any adverse effects experienced by the patient.

Conclusion[edit | edit source]

Doxercalciferol represents an important option in the management of secondary hyperparathyroidism in patients with CKD. Its ability to effectively reduce PTH levels, while managing calcium and phosphorus balance, makes it a valuable tool in preventing the bone disease associated with this condition.